Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference
October 29 2019 - 8:30AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced that Dr. Michael
Gutch, Chief Business Officer and Chief Financial Officer, will be
hosting a fireside chat at the 28th Annual Credit Suisse Healthcare
Conference being held November 11-13, 2019 in Scottsdale, AZ.
Details of the presentation are below: |
Event: |
28th Annual Credit Suisse Healthcare Conference |
Location:
|
The Phoenician |
Date: |
Tuesday, November 12, 2019 |
Time: |
4:45 – 5:15 PM MST |
Additionally, Dr. Gutch will hold 1-on-1
investor meetings at the conference. Investors attending the
conference who are interested in meeting with Company management
should contact their Credit Suisse representatives.
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including
sulbactam-durlobactam (targeting Acinetobacter
baumannii infections), zoliflodacin (targeting Neisseria
gonorrhoeae), and ETX0282CPDP
(targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information,
visit www.entasistx.com.
Entasis Company Contact Kyle
Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations Contact Tram Bui The Ruth
Group (646) 536-7035 tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2023 to Apr 2024